Please login to the form below

Not currently logged in
Email:
Password:

neutropaenia

This page shows the latest neutropaenia news and features for those working in and with pharma, biotech and healthcare.

Neulasta rival from Teva cleared in EU

Neulasta rival from Teva cleared in EU

Lonquex offers competition to Amgen drug in neutropaenia. Teva Pharmaceutical has been given a green light by the European Commission (EC) for Lonquex, a rival to Amgen's blockbuster Neulasta. ... Lonquex (lipegfilgrastim) has been approved to reduce the

Latest news

  • Lonza ends biosimilars deal with Teva Lonza ends biosimilars deal with Teva

    Teva's current efforts in the area include tbo-filgrastim - a biosimilar version of Amgen's Neupogen, which is approved for use  to hasten recovery from instances of neutropaenia in certain

  • R&D news in brief

    ìThe drug appears to be well tolerated, with thrombocytopaenia and neutropaenia, being the main side effects that require careful monitoring.î.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
foxandcat.online

some pressure is helpful but too much of the wrong sort quickly takes its toll. we help creatove agenices manage...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...